Volume | 25,423 |
|
|||||
News | - | ||||||
Day High | 1.7299 | Low High |
|||||
Day Low | 1.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cocrystal Pharma Inc | COCP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.57 | 1.57 | 1.7299 | 1.63 | 1.59 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
161 | 25,423 | $ 1.66 | $ 42,249 | - | 1.325 - 3.285 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 185 | $ 1.63 | USD |
Cocrystal Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.79M | 10.17M | - | 2.6M | -17.98M | -1.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cocrystal Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COCP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.52 | 1.7299 | 1.4885 | 1.55 | 14,653 | 0.11 | 7.24% |
1 Month | 1.50 | 1.7299 | 1.35 | 1.53 | 13,076 | 0.13 | 8.67% |
3 Months | 1.50 | 1.74 | 1.325 | 1.49 | 14,233 | 0.13 | 8.67% |
6 Months | 1.64 | 1.99 | 1.325 | 1.63 | 16,340 | -0.01 | -0.61% |
1 Year | 2.50 | 3.285 | 1.325 | 2.17 | 22,439 | -0.87 | -34.80% |
3 Years | 15.72 | 41.52 | 1.325 | 19.17 | 1,831,043 | -14.09 | -89.63% |
5 Years | 30.7536 | 49.20 | 1.325 | 18.89 | 2,024,404 | -29.12 | -94.70% |
Cocrystal Pharma Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |